(BBIO) BridgeBio Pharma - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US10806X1028
TTR Stabilizer, FGFR Inhibitor, CaSR Antagonist, Glycosylation Pro-Drug
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.3% |
| Value at Risk 5%th | 79.9% |
| Relative Tail Risk | -12.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.97 |
| Alpha | 154.23 |
| CAGR/Max DD | 2.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.357 |
| Beta | 1.065 |
| Beta Downside | 0.918 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.08% |
| Mean DD | 20.86% |
| Median DD | 20.42% |
Description: BBIO BridgeBio Pharma November 04, 2025
BridgeBio Pharma (NASDAQ: BBIO) is a commercial-stage biopharma focused on developing small-molecule and gene-therapy treatments for rare genetic diseases and oncology indications.
Its pipeline includes:
- Attruby – an oral transthyretin (TTR) stabilizer in late-stage development for ATTR-CM, a progressive amyloidosis affecting the heart.
- Low-dose infigratinib – an FGFR1-3 selective tyrosine-kinase inhibitor being evaluated in a Phase 3 double-blind trial for achondroplasia and in a Phase 2/3 study for hypochondroplasia.
- Encaleret – a calcium-sensing-receptor antagonist in Phase 3 for autosomal-dominant hypocalcemia type 1 (ADH1).
- BBP-418 – a glycosylation-substrate pro-drug in Phase 3 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
BridgeBio also pursues programs in Mendelian genetics, oncology, and gene-therapy platforms, leveraging collaborations with Alexion, Stanford, Leidos Biomedical, and Novartis.
Key recent metrics (as of Q3 2024): market capitalization ≈ $2.3 B, cash and equivalents of $550 M providing ~18 months of runway at current burn, and a 2023-2024 revenue run-rate of $120 M driven primarily by Attruby sales in Europe.
Sector-wide, the rare-disease biotech market is expanding at a CAGR of ~12 % (2022-2027) as payer frameworks increasingly accommodate high-price, high-impact therapies, which underpins BridgeBio’s growth outlook.
For a deeper, data-rich evaluation of BBIO’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-797.1m TTM) > 0 and > 6% of Revenue (6% = 21.2m TTM) |
| FCFTA -0.60 (>2.0%) and ΔFCFTA 9.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 176.0% (prev 140.2%; Δ 35.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.59 (>3.0%) and CFO -584.8m > Net Income -797.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (190.5m) change vs 12m ago 1.06% (target <= -2.0% for YES) |
| Gross Margin 95.78% (prev 98.90%; Δ -3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.54% (prev 32.75%; Δ 9.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.63 (EBITDA TTM -677.3m / Interest Expense TTM 121.3m) >= 6 (WARN >= 3) |
Altman Z'' -14.58
| (A) 0.62 = (Total Current Assets 839.4m - Total Current Liabilities 216.6m) / Total Assets 998.2m |
| (B) -3.63 = Retained Earnings (Balance) -3.63b / Total Assets 998.2m |
| warn (B) unusual magnitude: -3.63 — check mapping/units |
| (C) -0.82 = EBIT TTM -682.6m / Avg Total Assets 831.6m |
| (D) -1.24 = Book Value of Equity -3.63b / Total Liabilities 2.92b |
| Total Rating: -14.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.93
| 1. Piotroski 1.0pt |
| 2. FCF Yield -3.81% |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.96 |
| 5. Debt/Ebitda -1.80 |
| 7. RoE 46.63% |
| 8. Rev. Trend 46.69% |
| 9. EPS Trend -3.37% |
What is the price of BBIO shares?
As of December 10, 2025, the stock is trading at USD 71.67 with a total of 1,711,529 shares traded.
Over the past week, the price has changed by +0.29%, over one month by +14.11%, over three months by +33.96% and over the past year by +142.95%.
Over the past week, the price has changed by +0.29%, over one month by +14.11%, over three months by +33.96% and over the past year by +142.95%.
Is BBIO a buy, sell or hold?
BridgeBio Pharma has received a consensus analysts rating of 4.37.
Therefore, it is recommended to buy BBIO.
- Strong Buy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84.7 | 18.1% |
| Analysts Target Price | 84.7 | 18.1% |
| ValueRay Target Price | 79.3 | 10.6% |
BBIO Fundamental Data Overview December 06, 2025
Market Cap USD = 14.41b (14.41b USD * 1.0 USD.USD)
P/S = 40.7228
P/B = 123.6828
Beta = 1.269
Revenue TTM = 353.8m USD
EBIT TTM = -682.6m USD
EBITDA TTM = -677.3m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 5.29m USD (from shortTermDebt, last quarter)
Debt = 1.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.22b USD (from netDebt column, last quarter)
Enterprise Value = 15.62b USD (14.41b + Debt 1.86b - CCE 645.9m)
Interest Coverage Ratio = -5.63 (Ebit TTM -682.6m / Interest Expense TTM 121.3m)
FCF Yield = -3.81% (FCF TTM -595.2m / Enterprise Value 15.62b)
FCF Margin = -168.2% (FCF TTM -595.2m / Revenue TTM 353.8m)
Net Margin = -225.3% (Net Income TTM -797.1m / Revenue TTM 353.8m)
Gross Margin = 95.78% ((Revenue TTM 353.8m - Cost of Revenue TTM 14.9m) / Revenue TTM)
Gross Margin QoQ = 94.56% (prev 96.70%)
Tobins Q-Ratio = 15.65 (Enterprise Value 15.62b / Total Assets 998.2m)
Interest Expense / Debt = 0.63% (Interest Expense 11.7m / Debt 1.86b)
Taxrate = 0.83% (-1.54m / -186.5m)
NOPAT = -677.0m (EBIT -682.6m * (1 - 0.83%)) [loss with tax shield]
Current Ratio = 3.88 (Total Current Assets 839.4m / Total Current Liabilities 216.6m)
Debt / Equity = -0.96 (negative equity) (Debt 1.86b / totalStockholderEquity, last quarter -1.93b)
Debt / EBITDA = -1.80 (negative EBITDA) (Net Debt 1.22b / EBITDA -677.3m)
Debt / FCF = -2.04 (negative FCF - burning cash) (Net Debt 1.22b / FCF TTM -595.2m)
Total Stockholder Equity = -1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = -79.85% (Net Income -797.1m / Total Assets 998.2m)
RoE = 46.63% (negative equity) (Net Income TTM -797.1m / Total Stockholder Equity -1.71b)
RoCE = -481.7% (out of range, set to none) (EBIT -682.6m / Capital Employed (Equity -1.71b + L.T.Debt 1.85b))
RoIC = -625.6% (out of range, set to none) (NOPAT -677.0m / Invested Capital 108.2m)
WACC = 8.88% (E(14.41b)/V(16.27b) * Re(9.94%) + D(1.86b)/V(16.27b) * Rd(0.63%) * (1-Tc(0.01)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.50%
Fair Price DCF = unknown (Cash Flow -595.2m)
EPS Correlation: -3.37 | EPS CAGR: 14.10% | SUE: 0.39 | # QB: 0
Revenue Correlation: 46.69 | Revenue CAGR: 81.59% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.60 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.77 | Chg30d=-0.047 | Revisions Net=+1 | Growth EPS=+44.4% | Growth Revenue=+79.6%
P/S = 40.7228
P/B = 123.6828
Beta = 1.269
Revenue TTM = 353.8m USD
EBIT TTM = -682.6m USD
EBITDA TTM = -677.3m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 5.29m USD (from shortTermDebt, last quarter)
Debt = 1.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.22b USD (from netDebt column, last quarter)
Enterprise Value = 15.62b USD (14.41b + Debt 1.86b - CCE 645.9m)
Interest Coverage Ratio = -5.63 (Ebit TTM -682.6m / Interest Expense TTM 121.3m)
FCF Yield = -3.81% (FCF TTM -595.2m / Enterprise Value 15.62b)
FCF Margin = -168.2% (FCF TTM -595.2m / Revenue TTM 353.8m)
Net Margin = -225.3% (Net Income TTM -797.1m / Revenue TTM 353.8m)
Gross Margin = 95.78% ((Revenue TTM 353.8m - Cost of Revenue TTM 14.9m) / Revenue TTM)
Gross Margin QoQ = 94.56% (prev 96.70%)
Tobins Q-Ratio = 15.65 (Enterprise Value 15.62b / Total Assets 998.2m)
Interest Expense / Debt = 0.63% (Interest Expense 11.7m / Debt 1.86b)
Taxrate = 0.83% (-1.54m / -186.5m)
NOPAT = -677.0m (EBIT -682.6m * (1 - 0.83%)) [loss with tax shield]
Current Ratio = 3.88 (Total Current Assets 839.4m / Total Current Liabilities 216.6m)
Debt / Equity = -0.96 (negative equity) (Debt 1.86b / totalStockholderEquity, last quarter -1.93b)
Debt / EBITDA = -1.80 (negative EBITDA) (Net Debt 1.22b / EBITDA -677.3m)
Debt / FCF = -2.04 (negative FCF - burning cash) (Net Debt 1.22b / FCF TTM -595.2m)
Total Stockholder Equity = -1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = -79.85% (Net Income -797.1m / Total Assets 998.2m)
RoE = 46.63% (negative equity) (Net Income TTM -797.1m / Total Stockholder Equity -1.71b)
RoCE = -481.7% (out of range, set to none) (EBIT -682.6m / Capital Employed (Equity -1.71b + L.T.Debt 1.85b))
RoIC = -625.6% (out of range, set to none) (NOPAT -677.0m / Invested Capital 108.2m)
WACC = 8.88% (E(14.41b)/V(16.27b) * Re(9.94%) + D(1.86b)/V(16.27b) * Rd(0.63%) * (1-Tc(0.01)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.50%
Fair Price DCF = unknown (Cash Flow -595.2m)
EPS Correlation: -3.37 | EPS CAGR: 14.10% | SUE: 0.39 | # QB: 0
Revenue Correlation: 46.69 | Revenue CAGR: 81.59% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.60 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.77 | Chg30d=-0.047 | Revisions Net=+1 | Growth EPS=+44.4% | Growth Revenue=+79.6%
Additional Sources for BBIO Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle